Regulus therapeutics inc. (RGLS)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Revenues:
Revenue from Contract with Customer, Excluding Assessed Tax

6,832

72

72

1,194

-

-

-

-

-

-

Total revenues

-

-

-

-

20,759

7,669

19,569

12,700

13,789

8,601

Operating expenses:
Research and development

12,349

33,975

53,192

64,305

56,387

41,046

29,942

20,342

17,289

20,178

General and administrative

11,317

12,860

17,011

18,391

19,130

11,533

7,429

4,932

3,637

3,921

Total operating expenses

23,666

46,835

70,203

82,696

75,517

52,579

37,371

25,274

20,926

24,099

Loss from operations

-16,834

-46,763

-70,131

-81,502

-54,758

-44,910

-17,802

-12,574

-7,137

-15,498

Other income (expense):
Interest and other income

374

459

752

844

855

388

292

110

129

271

Interest and other expense

2,131

2,343

2,723

1,182

52

39

36

247

388

362

Loss on extinguishment of debt

-

-

-

-

-

-

-

-1,738

-

-

Loss from valuation of convertible note payable

-

-

-

-

-1,811

-12,118

-1,145

-2,969

-

-

Loss before income taxes

-18,591

-48,647

-72,102

-81,840

-55,766

-56,679

-18,691

-17,418

-7,396

-15,589

Income tax benefit

1

62

-197

-4

-18

1

-23

-10

206

-30

Net Income (Loss) Attributable to Parent

-18,592

-48,709

-71,905

-81,836

-55,748

-56,680

-18,668

-17,408

-7,602

-15,559

Unrealized gain on short-term investments, net

-

-

-11

10

64

-181

36

15

-80

13

Comprehensive loss

-

-

-71,916

-81,826

-55,684

-56,861

-18,632

-17,393

-7,682

-15,546

Net loss per share, basic and diluted (in dollars per share)

-1.08

-5.59

-11.47

-18.59

-1.08

-1.29

-0.49

-2.12

-85.82

-

Weighted average shares used to compute basic and diluted net loss per share (in shares)

17,260

8,718

6,269

4,401

51,411

44,090

38,479

8,212,538

88,582

-

Revenue under collaborations
Total revenues

6,832

72

-

-

-

-

-

-

-

-

Strategic Alliances and Collaborations
Total revenues

-

-

72

1,194

-

-

-

-

-

-